• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization

New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization

by Truveta Research | Jun 13, 2025 | Research, Research Insights

Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Moderate adherence was observed for...
Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers

Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers

by Truveta staff | May 8, 2025 | News

With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta is leading a new era in cancer research, delivering an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and...
Study exploring syphilis infections among US adults published in American Journal of Preventative Medicine

Study exploring syphilis infections among US adults published in American Journal of Preventative Medicine

by Truveta staff | Apr 15, 2025 | Research, Research Insights

Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2017 and October 2024. During the early months of the COVID-19 pandemic, the rate of syphilis incidence (e.g., new infection) increased significantly, reaching a...
« Older Entries

Share this


Recent posts

  • New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization
  • Understanding the impact of the COVID-19 pandemic on childhood MMR vaccination patterns
  • Shifting trends in TKA fixation: Real-world evidence on the changing landscape of cemented vs uncemented TKA

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice